RESUMEN
The initial observations linking vitamin D to type 2 diabetes in humans came from studies showing that both healthy and diabetic subjects had a seasonal variation of glycemic control. Currently, there is evidence supporting that vitamin D status is important to regulate some pathways related to type 2 diabetes development. Since the activation of inflammatory pathways interferes with normal metabolism and disrupts proper insulin signaling, it is hypothesized that vitamin D could influence glucose homeostasis by modulating inflammatory response. Human studies investigating the impact of vitamin D supplementation on inflammatory biomarkers of subjects with or at high risk of developing type 2 diabetes are scarce and have generated conflicting results. Based on available clinical and epidemiological data, the positive effects of vitamin D seem to be primarily related to its action on insulin secretion and sensitivity and secondary to its action on inflammation. Future studies specifically designed to investigate the role of vitamin D on type 2 diabetes using inflammation as the main outcome are urgently needed in order to provide a more robust link between vitamin D, inflammation and type 2 diabetes.
Asunto(s)
Diabetes Mellitus Tipo 2/metabolismo , Inflamación/metabolismo , Vitamina D/metabolismo , Adulto , Anciano , Animales , Biomarcadores/metabolismo , Diabetes Mellitus Tipo 2/complicaciones , Femenino , Humanos , Inflamación/complicaciones , Insulina/metabolismo , Resistencia a la Insulina , Secreción de Insulina , Masculino , Persona de Mediana Edad , Deficiencia de Vitamina D/complicacionesRESUMEN
OBJECTIVE: Information regarding nutrition and body composition in patients diagnosed with osteogenesis imperfecta (OI) is scarce. In the present study, nutritional status, bone mineral density, and biochemical parameters of subjects with OI were evaluated. METHODS: Patients with type I OI (n = 13) and type III OI (n = 13) and healthy controls (n = 8) were selected. Nutritional status and bone mineral density were assessed by a 3-d food diary and dual-energy X-ray absorptiometry at the lumbar spine, respectively. Body mass index, serum albumin, calcium, creatinine, cross-linked C-telopeptide, parathyroid hormone, and 25-hydroxivitamin D(3) were also evaluated. RESULTS: Patients with OI had lower bone mineral density (P < 0.05 versus controls). Patients with type III OI had the highest body mass index (P < 0.05 versus patients with type I OI and controls) and the lowest lean body mass (P < 0.05 versus patients with type I OI and controls). In patients with OI, the number of fractures was positively correlated with body mass index (r = 0.581, P = 0.002) and the percentage of body fat (r = 0.451, P = 0.027) and negatively correlated to lean body mass (r = -0.523, P = 0.009). Even when taking dietary supplements, 58% and 12% of subjects with OI did not achieve the calcium and vitamin D recommendations, respectively. CONCLUSIONS: Body composition is a risk factor for bone fractures in subjects with OI. Individualized nutritional support is recommended not only to improve body composition but also to potentiate pharmacologic and physical therapies.
Asunto(s)
Composición Corporal , Densidad Ósea , Fracturas Óseas/prevención & control , Necesidades Nutricionales , Apoyo Nutricional , Obesidad/complicaciones , Osteogénesis Imperfecta/terapia , Tejido Adiposo , Adolescente , Adulto , Compartimentos de Líquidos Corporales , Índice de Masa Corporal , Calcio/administración & dosificación , Calcio/sangre , Calcio/deficiencia , Estudios de Casos y Controles , Suplementos Dietéticos , Femenino , Fracturas Óseas/etiología , Humanos , Masculino , Estado Nutricional , Obesidad/sangre , Osteogénesis Imperfecta/sangre , Osteogénesis Imperfecta/complicaciones , Prevalencia , Vitamina D/administración & dosificación , Vitamina D/sangre , Deficiencia de Vitamina D/epidemiología , Adulto JovenRESUMEN
Folic acid (FA) supplementation during carcinogenesis is controversial. Considering the impact of liver cancer as a public health problem and mandatory FA fortification in several countries, the role of FA supplementation in hepatocarcinogenesis should be elucidated. We evaluated FA supplementation during early hepatocarcinogenesis. Rats received daily 0.08 mg (FA8 group) or 0.16 mg (FA16 group) of FA/100 g body weight or water (CO group, controls). After a 2-week treatment, animals were subjected to the "resistant hepatocyte" model of hepatocarcinogenesis (initiation with diethylnitrosamine, selection/promotion with 2-acetylaminofluorene and partial hepatectomy) and euthanized after 8 weeks of treatment. Compared to the CO group, the FA16 group presented: reduced (p < 0.05) number of persistent and increased (p < 0.05) number of remodeling glutathione S-transferase (GST-P) positive preneoplastic lesions (PNL); reduced (p < 0.05) cell proliferation in persistent GST-P positive PNL; decreased (p < 0.05) hepatic DNA damage; and a tendency (p < 0.10) for decreased c-myc expression in microdissected PNL. Regarding all these parameters, no differences (p > 0.05) were observed between CO and FA8 groups. FA-treated groups presented increased hepatic levels of S-adenosylmethionine but only FA16 group presented increased S-adenosylmethionine/S-adenosylhomocysteine ratio. No differences (p > 0.05) were observed between experimental groups regarding apoptosis in persistent and remodeling GST-P positive PNL, and global DNA methylation pattern in microdissected PNL. Altogether, the FA16 group, but not the FA8 group, presented chemopreventive activity. Reversion of PNL phenotype and inhibition of DNA damage and of c-myc expression represent relevant FA cellular and molecular effects.
Asunto(s)
Transformación Celular Neoplásica/efectos de los fármacos , Suplementos Dietéticos , Ácido Fólico/farmacología , Neoplasias Hepáticas Experimentales/prevención & control , Animales , Apoptosis/efectos de los fármacos , Peso Corporal/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Transformación Celular Neoplásica/genética , Transformación Celular Neoplásica/metabolismo , Quimioprevención , Daño del ADN , Metilación de ADN , Expresión Génica , Genes myc , Glutatión Transferasa/metabolismo , Hígado/anatomía & histología , Hígado/metabolismo , Hígado/patología , Neoplasias Hepáticas Experimentales/genética , Neoplasias Hepáticas Experimentales/metabolismo , Masculino , Tamaño de los Órganos/efectos de los fármacos , Lesiones Precancerosas/genética , Lesiones Precancerosas/metabolismo , Lesiones Precancerosas/prevención & control , Ratas , Ratas Wistar , S-Adenosilhomocisteína/metabolismo , S-Adenosilmetionina/metabolismoRESUMEN
A ingestão de folato é inversamente associada com o risco de diversos cânceres. Apesar da deficiência dessa vitamina ser classicamente considerada fator de risco para câncer de fígado, não existem estudos avaliando o efeito da suplementação com ácido fólico (AF) durante as etapas iniciais da hepatocarcinogênese. Assim, o objetivo do presente estudo foi avaliar o efeito da suplementação com AF continuamente durante as etapas de iniciação e seleção/promoção da hepatocarcinogênese em ratos. Os animais receberam diariamente 0,08 mg (grupo AF8) ou 0,16 mg (grupo AF16) de AF/100 g de peso corpóreo ou água (grupo controle [GC]). Após duas semanas de tratamento, todos os animais foram submetidos ao modelo de hepatocarcinogênese do Hepatócito Resistente (iniciação com dietilnitrosamina, seleção/promoção com 2-acetilaminofluoreno e hepatectomia parcial a 70%). A eutanásia dos animais ocorreu após 8 semanas de tratamento. Quando comparado ao GC, o grupo AF16, mas não o AF8, apresentou menores nódulos macroscópicos (p<0,05), menor (p<0,05) número de lesões pré-neoplásicas (LPN) persistentes, maior (p<0,05) número de LPN em remodelação, menor (p<0,05) proliferação celular nas LPN persistentes, menos (p<0,05) danos no DNA hepático e tendência (p<0,10) a apresentar menor expressão de c-myc em LPN microdissecadas. Não foram observadas diferenças significativas (p>0,05) entre os grupos experimentais com relação à indução de apoptose nas LPN persistentes e em remodelação bem como no padrão de metilação global do DNA em LPN microdissecadas. Em resumo, a suplementação com AF durante as etapas iniciais da hepatocarcinogênese resultou em atividade quimiopreventiva de forma dose-efeito. Alteração no fenótipo das LPN, inibição de danos no DNA hepático e da expressão de c-myc representam relevantes efeitos celulares e moleculares dessa vitamina.
Dietary intake of folate is inversely associated with the risk of several malignancies. Although folate deficiency is associated with liver cancer, there is no data on folic acid (FA) supplementation during hepatocarcinogenesis. The aim of the present study was to evaluate the effect of FA supplementation during early hepatocarcinogenesis. Rats receiving daily 0.08 mg (FA8 group) or 0.16 mg (FA16 group) of FA/100 g body weight or water (CO group, controls) were used. After a 2 week-treatment, all animals were submitted to the resistant hepatocyte model of hepatocarcinogenesis (initiation with diethylnitrosamine, selection/promotion with 2-acetylaminofluorene and partial hepatectomy). All animals were euthanized after 8 weeks of treatment. When compared to CO group, FA16 group, but not FA8 group, presented: smaller (p < 0.05) macroscopic nodules; reduced (p < 0.05) number of persistent and increased (p < 0.05) number of remodeling preneoplastic lesions (PNL); reduced (p < 0.05) cell proliferation in persistent PNL; decreased (p < 0.05) hepatic DNA damage; and a tendency (p < 0.10) of decreased c-myc expression in microdissected PNL. No differences (p > 0.05) were observed between CO, FA8 and FA16 groups regarding apoptosis in both persistent and remodeling PNL, and global DNA methylation pattern in microdissected PNL. In conclusion, FA supplementation during early hepatocarcinogenesis resulted in a dose-response chemopreventive activity. Reversion of PNL phenotype and inhibition of DNA damage and of c-myc expression represent relevant FA cellular and molecular effects.
Asunto(s)
Animales , Masculino , Ratas , Adulto Joven , Ácido Fólico/inmunología , Suplementos Dietéticos , Prevención de Enfermedades , Quimioterapia , Neoplasias Hepáticas/genética , Reacciones Bioquímicas , Ciencias de la Nutrición , Vitaminas en la Dieta/uso terapéuticoRESUMEN
PURPOSE: To study farnesol (FOH) effects on liver regeneration after 70% partial hepatectomy (PH) in rats. METHODS: Animals received FOH (25 mg/100 g body weight/day) or corn oil (CO, 0.25 mL/100 g body weight/day, controls). After a 2 week-treatment, all animals were subjected to PH and euthanized at different time points (0 h, 0.5 h, 4 h, 8 h, 18 h and 24 h) after surgery. Hepatic cell proliferation (PCNA positive nuclei) and apoptosis (fluorescence microscopy) were evaluated. RESULTS: Compared to CO treatment, FOH treatment inhibited (p<0.05) cell proliferation at 24h (S phase of the cell cycle) after PH. This was preceded by an induction of apoptosis 0.5 h (p<0.05; G(0)/G(1) transition phase) after surgery. CONCLUSION: The results of the present study suggest that apoptosis induction could be associated with the reduced number of cells at the S phase observed in FOH group. These novel in vivo data reinforce FOH as a promising chemopreventive and therapeutic agent against cancer.
Asunto(s)
Apoptosis/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Farnesol/farmacología , Hepatectomía/métodos , Regeneración Hepática/efectos de los fármacos , Animales , Bovinos , ADN/biosíntesis , Modelos Animales de Enfermedad , Evaluación Preclínica de Medicamentos , Masculino , Distribución Aleatoria , Ratas , Ratas WistarRESUMEN
PURPOSE: To study farnesol (FOH) effects on liver regeneration after 70 percent partial hepatectomy (PH) in rats. METHODS: Animals received FOH (25 mg/100 g body weight/day) or corn oil (CO, 0.25 mL/100 g body weight/day, controls). After a 2 week-treatment, all animals were subjected to PH and euthanized at different time points (0 h, 0.5 h, 4 h, 8 h, 18 h and 24 h) after surgery. Hepatic cell proliferation (PCNA positive nuclei) and apoptosis (fluorescence microscopy) were evaluated. RESULTS: Compared to CO treatment, FOH treatment inhibited (p<0.05) cell proliferation at 24h (S phase of the cell cycle) after PH. This was preceded by an induction of apoptosis 0.5 h (p<0.05; G0/G1 transition phase) after surgery. CONCLUSION: The results of the present study suggest that apoptosis induction could be associated with the reduced number of cells at the S phase observed in FOH group. These novel in vivo data reinforce FOH as a promising chemopreventive and therapeutic agent against cancer.
OBJETIVO: Estudar o efeito do farnesol (FOH) durante a regeneração hepática em ratos submetidos à Hepatectomia Parcial (HP) a 70 por cento. MÉTODOS: Os animais foram tratados com FOH (25 mg/100g de peso corpórel/dia) ou óleo de milho (OM, 0,25 mL/100g de peso corpóreo/dia, grupo controle). Depois de 2 semanas de tratamento, todos os animais foram submetidos à HP e eutanaziados em diferentes momentos (0h, 30min., 4h, 8h, 18h, 24h.) após o procedimento cirúrgico. Foi avaliada a proliferação celular (imunohistoquímica para PCNA) e a apoptose (microscopia de fluorescência). RESULTADOS: Em comparação aos animais controles, animais tratados com FOH apresentaram menor (p<0,05) proliferação celular 24h. (fase S do ciclo celular) após a HP. Tal efeito foi precedido de uma indução de apoptose 30min. (p<0,05; transição entre as fases G0/G1 do ciclo celular) após a cirurgia. CONCLUSÃO: Os resultados do presente estudo sugerem que a indução da apoptose pode estar associada com o menor número de células na fase S observadas nos animais tratados com FOH. Essa nova evidência in vivo reforça o farnesol como um promissor agente preventivo e terapêutico contra o câncer.
Asunto(s)
Animales , Bovinos , Masculino , Ratas , Apoptosis/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Farnesol/farmacología , Hepatectomía/métodos , Regeneración Hepática/efectos de los fármacos , Modelos Animales de Enfermedad , ADN , Evaluación Preclínica de Medicamentos , Distribución Aleatoria , Ratas WistarRESUMEN
Chemopreventive activities of all-trans retinoic acid (AtRA), 9-cis retinoic acid (9cRA), retinol (ROL) and beta-carotene (betaC) were evaluated during hepatocarcinogenesis. Rats received 1 mg/100 g body wt AtRA (AtRA group), 9cRA (9cRA group), ROL (ROL group), 7 mg/100 g body wt betaC (betaC group) or corn oil (CO group, controls). Hepatocyte nodule incidence was reduced (P < 0.05) in betaC group (46%), but not (P > 0.05) in AtRA (92%), 9cRA (92%) and ROL (82%) groups, compared with the CO group (100%). Multiplicity of these preneoplastic lesions (PNL) was different (P < 0.05) between CO group (44 +/- 9) and 9cRA (11 +/- 4), ROL (7 +/- 3) and betaC (4 +/- 2) groups, except for AtRA group (27 +/- 9; P > 0.05). Number/cm(2) liver section, mean area (mm(2)) and percent liver section area occupied by total (persistent + remodeling) placental glutathione S-transferase (GST-P) positive PNL was reduced (P < 0.05) in AtRA (107 +/- 13; 0.12 +/- 0.06; 13.9 +/- 3.9), 9cRA (71 +/- 12; 0.12 +/- 0.06; 6.8 +/- 2.2), ROL (96 +/- 13; 0.11 +/- 0.22; 6.8 +/- 2.0) and betaC (106 +/- 13; 0.08 +/- 0.03; 10.8 +/- 2.5) groups compared with CO group (166 +/- 14; 0.18 +/- 0.09; 28.6 +/- 5.2). Percent of remodeling GST-P positive PNL was increased (P < 0.05) in 9cRA (92 +/- 1), ROL (96 +/- 1) and betaC (93 +/- 1) groups, but not (P > 0.05) in AtRA group (90 +/- 2), compared with the CO group (86 +/- 1). Compared with the CO group, all groups present in PNL reduced (P < 0.05) cell proliferation and no differences (P > 0.05) in apoptosis. DNA damage [comet length (mum)] was reduced (P < 0.05) in ROL (87.9 +/- 2.6) and betaC (89.2 +/- 4.0) groups, but not in AtRA (94.8 +/- 4.1) and 9cRA (94.2 +/- 1.5) groups, compared with the CO group (100.4 +/- 3.9). AtRA, 9cRA, ROL and betaC presented chemopreventive activities against hepatocarcinogenesis. These involve inhibition of cell proliferation, but not induction of apoptosis. Increased remodeling of GST-P positive PNL relates to 9cRA, ROL and betaC actions, while inhibition of DNA damage relates to ROL and betaC actions.